Sales Beat Estimates by 6.7%, But the Stock Sank — What Coty's Earnings Are Hiding
Overview
Coty posted Q4 FY2026 net revenue of $1.27B, beating consensus by 6.7%, but adjusted EPS of -$0.02 missed the -$0.01 estimate. The stock, up more than 10% in the regular session, fell 4.6% after hours once results were released. Much of the headline balance-sheet improvement came not from an operating recovery but from the Wella and Gucci Beauty divestitures, and the new interim CEO's guidance covers only half the fiscal year, not the full year.
On August 19, Coty Inc. reported results for the fourth quarter of fiscal 2026 (July 2025–June 2026). Net revenue came in at $1.27B, beating the roughly $1.19B Wall Street expected by 6.7% — on the surface, a clean beat. Yet the stock, which had climbed more than 10% during the regular session, fell 4.6% in after-hours trading once the results were released, and the slide continued the next day. Sales won, so why did the market turn its back? The answer sits just beneath the headline number — adjusted earnings per share (EPS) of -$0.02 missed the -$0.01 consensus, and much of the cash behind this quarter's apparent improvement came not from operations but from two large asset sales.
The Quarter and the Year, by the Numbers
| Metric | Q4 (Apr–Jun '26) | Full Year (FY2026) |
|---|---|---|
| Net revenue | $1.27B (reported +1%, organic -1%) | $5.81B (reported -2%, organic -5%) |
| Prestige segment | $771.8M (organic -0.5%) | $3.81B (organic -4%) |
| Consumer Beauty segment | $497.4M (organic -3%) | $2.00B (organic -7%) |
| Adjusted gross margin | 60.9% (-140bp) | 63.0% (-190bp) |
| Adjusted operating income | $39.5M (prior year $67.7M, -27%) | $626.7M (prior year $852.9M, -27%) |
| Adjusted EBITDA | $93.6M (-26%, margin 7.4%) | $846.9M (-22%, margin 14.6%) |
| Adjusted EPS | -$0.02 (estimate -$0.01) | $0.21 (prior year $0.22) |
| Free cash flow (FCF) | $72.6M (prior year $34.9M) | $348.2M (prior year $277.6M) |
Prestige (61% of total revenue) held up better, with fragrance and color cosmetics growth offsetting a skincare decline for a modest 0.5% organic drop in Q4. Consumer Beauty (39%), by contrast, grew in mass skincare but stayed weak in color cosmetics, falling 3% in Q4 and 7% for the full year — a clearly sharper decline than Prestige. By region, the Americas (+$43.5M) and Asia Pacific (+$18.6M, on China, Southeast Asia and travel-retail growth) both grew, while EMEA (-$45.3M) fell on weakness in the Middle East, Germany and Central and Eastern Europe. The company said the Middle East conflict alone weighed on Q4 organic growth by roughly one percentage point.
The Core Insight — Divestitures, Not Operations, Funded the Improvement
Coty's release leaned heavily on how much its financial metrics improved. Full-year FCF rose to $348.2M from $277.6M a year earlier, total debt fell to $3.09B from $3.22B at the end of March, and the net-debt-to-adjusted-EBITDA ratio held at a manageable 3.4x. The company said it delivered "more than $250M in productivity and fixed-cost savings in fiscal 2026" to offset inflation and weaker volumes.
But follow the timeline of that improvement and a different picture emerges. In December 2025 — Coty's fiscal Q3 — the company sold its remaining stake in Wella for $750M in cash. Then, around the same time as this earnings release, in July 2026, Coty agreed with Kering to an early exit from the Gucci Beauty license: $250M upon signing, plus up to another $150M (including a conditional $30M) by September 2027, ending the license roughly a year early, on June 30, 2027, instead of its original term. The company said it plans to use these proceeds for "debt reduction, reinvestment in core prestige fragrance and beauty brands, and organizational optimization" — meaning a meaningful share of the balance-sheet improvement Coty is touting came not from money the business earned, but from money raised by selling parts of the portfolio. And the shrinking continues: the company itself warned that "the early return of the Gucci Beauty license will reduce revenue and profit in fiscal 2028." In effect, Coty is buying cash and debt reduction today at the cost of becoming a smaller company tomorrow.
The second thing worth flagging is a gap in the guidance. Coty's previous CEO, Sue Nabi, stepped down in January after a five-year tenure; the company named Markus Strobel — a 33-year P&G veteran who most recently led its global Skin & Personal Care business — as Executive Chairman and Interim CEO, effective January 2026. Yet this earnings release offered guidance only for Q1 FY2027 (organic revenue down a low-to-mid single-digit percentage, adjusted gross margin down 50–100bp) and for H1 FY2027 (FCF above $300M) — no full-year FY2027 guidance at all. The company described this as reflecting "completion of the strategic review and the early execution phase of Coty.Curated." But for a company of Coty's size to skip full-year guidance entirely is unusual. It reads more accurately as a sign that, ahead of a permanent CEO appointment, even the company itself isn't confident about how the full year will play out.
Business Impact — A Shrinking Prestige Base and a Structurally Weak Mass Business
The early Gucci Beauty exit delivers near-term cash but cuts into the Prestige revenue base over the medium term. To offset it, Coty says it will concentrate resources on core fragrance franchises — Burberry, Calvin Klein, Hugo Boss — while building out newer additions such as Marc Jacobs Beauty (makeup) and Swarovski, Etro and Marni (fragrance). Whether these replacement brands can fill the gap Gucci Beauty leaves behind won't be testable until fiscal 2028.
The structural weakness in Consumer Beauty is the other open issue. It fell 3% organically in Q4 and 7% for the full year — a sharper decline than Prestige — with mass color cosmetics the weakest spot. Coty said it's simplifying under a program called "Color the Future," cutting SKUs and concentrating resources on a smaller number of proven hits, alongside a Consumer Beauty R&D reorganization and consolidation of global brand-marketing functions. This reads less like a plan to grow revenue again than a defensive move to protect profitability inside a shrinking base.
Practical Implications
- Finance/IR teams: When headline FCF and debt figures improve, separate what came from operating cash generation versus asset-sale proceeds. In a quarter like Coty's, with large divestitures overlapping, judging the trend from operating results alone risks a misread
- Beauty category buyers/MDs: The Gucci Beauty license ending in June 2027 has direct implications for future prestige fragrance and makeup buying and placement plans. Worth checking the domestic distribution strategy for the replacement brands (Marc Jacobs Beauty, Swarovski, Etro, Marni) in advance
- Competitive benchmarking teams: Set alongside Estée Lauder's Q4 beat reported the same week (see our related article on its 66% adjusted EPS jump), the two companies' "improvement" is built on entirely different material — Estée Lauder's came from large-scale layoffs and cost cuts, Coty's from divestiture proceeds. Track whether each company's organic revenue growth actually improves on its own next quarter to judge whether either turnaround is real
- Travel-retail/duty-free MDs: Coty explicitly cited travel retail as one driver of its Asia Pacific growth — useful confirmation that the travel-retail channel still carries real weight in the fragrance category
Conclusion
Judged on revenue alone, Coty's fourth quarter is a beat. Look underneath, though, and three separate stories overlap — cash generated by divestitures rather than operations, a half-year guidance window from a still-uncertain interim leadership team, and a strategy of shrinking the company to repair its balance sheet. That likely explains why the market weighted the EPS miss and cautious guidance more heavily than the sales beat. The next real test of whether Coty's recovery is genuine comes once a permanent CEO is named and full-year guidance returns.
What struck me first about this release is that a sales beat and a stock sell-off arrived in the same breath. Chase the headline number alone and "beat estimates" reads as reassurance — but the market read the EPS miss and margin erosion underneath it correctly. This is a good reminder to check what a sales beat cost before taking comfort in it.
Second, on the Wella and Gucci Beauty sales: trimming the portfolio to cut debt isn't a bad strategy in itself. But these are cards you can only play once. Having sold Wella and now agreed to exit Gucci Beauty, I find myself wondering how many non-core assets Coty has left to sell. An improvement curve built on divestitures eventually runs out, and after that the company has to win purely on operating strength.
Finally, I think the guidance gap under an interim CEO says something to the wider industry. Korean retailers, too, often struggle to lay out concrete medium-term plans during a CEO transition and end up managing quarter to quarter instead. Coty's case is a useful reference point for how the market reads that vacuum — and for how quickly a permanent leadership decision needs to get made.